Pfizer Antiviral - Search News

Haleon, Pfizer

Why Pfizer sold its $3 billion stake in Haleon

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,

Reuters on MSN · 3d

Pfizer to sell $3 billion stake in Sensodyne maker Haleon

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.

Wall Street Journal · 3d

Pfizer Sells 700 Million Haleon Shares for $3.05 Billion

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.

MarketWatch · 3d

Pfizer Has Sold 700M Haleon Shares

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top

STAT3d

Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

11d

Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid ...

C&EN10d

Pfizer doubles down on AI partnership with antibody-drug conjugate deal

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

pharmaphorum2d

Pfizer bulks up in RSV with $525m takeover of ReViral

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

11don MSN

Paxlovid may help some long COVID patients: Research

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long ...

Wedmont Private Capital Sells 6,639 Shares of Pfizer Inc. (NYSE:PFE)

Wedmont Private Capital lessened its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 17.7% in the fourth ...

pharmaphorum8d

Pfizer's COVID boom goes on, as it eyes $22bn in Paxlovid sales this year

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results